Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Aim(s): To evaluate lanreotide autogel (LAN) plus TMZ in patients (pts) with progressive advanced/metastatic G1/G2 GEP-NET (or unknown primary).
Materials and methods: SONNET is an open, prospective, phase 2 study. The primary endpoint was the rate of disease control (DCR), defined as SD + PR + CR at 6 mo of a combination therapy of LAN and TEM. Non-functioning NET pts without progression at 6 mo were randomized to 6-mo LAN maintenance or watch and wait. Functioning NET pts with benefit continued on LAN.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof Marianne Pavel
To read results and conclusion, please login ...
Further abstracts you may be interested in